Eye tech incubator spins out third opthalmic company
This article was originally published in Clinica
ForSight Labs, an incubator company focused on ophthalmic technologies, has raised $6m in series A funding for its newly-formed third venture, ForSight VISION3. Participants in the financing round include Morgenthaler Ventures, Split Rock Partners and Versant Ventures. ForSight said it is currently assessing which the technologies that VISION3 will work on. The other two companies created by Menlo Park, California-based ForSight are Transcend Medical, which is focused on devices for managing glaucoma, and ForSight Newco II, which is developing a proprietary punctual plug drug delivery system. The latter was acquired by QLT in October 2007.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.